Filing Details

Accession Number:
0001104659-20-007260
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-01-27 19:01:46
Reporting Period:
2020-01-23
Accepted Time:
2020-01-27 19:01:46
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1270073 Intercept Pharmaceuticals Inc. ICPT Pharmaceutical Preparations (2834) 223868459
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1493811 Christian Weyer C/O Intercept Pharmaceuticals, Inc.
10 Hudson Yards, Floor 37
New York NY 10001
Evp, Research & Development No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-01-23 4,800 $0.00 18,560 No 4 A Direct
Common Stock Disposition 2020-01-27 723 $94.04 17,837 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Option to Purchase Common Stock Acquisiton 2020-01-23 7,900 $0.00 7,900 $99.66
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
7,900 2030-01-23 No 4 A Direct
Footnotes
  1. Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. The award shall be subject to a four-year vesting period, with the shares subject to the award vesting in four equal annual installments following the Vesting Commencement Date. The Vesting Commencement Date is January 1, 2020.
  2. This transaction was effected pursuant to a pre-existing Rule 10b5-1 trading plan adopted by the reporting person.
  3. The award shall be subject to a four-year vesting period, with 25% of the shares subject to the award vesting and becoming exercisable in an initial annual installment following the Vesting Commencement Date and 1/48th of the shares subject to the award vesting and becoming exercisable each month thereafter. The Vesting Commencement Date is January 1, 2020.